All
Zytiga-Containing Regimen Boosts Survival in Certain Patients With Prostate Cancer
May 6th 2022Treatment with androgen deprivation therapy in combination with Zytiga, docetaxel and prednisone improved radiographic progression-free survival and overall survival in patients with de novo metastatic castration-sensitive prostate cancer.
FDA Approves Enhertu for Subset of Patients with Metastatic Breast Cancer
May 5th 2022The FDA’s approval of Enhertu in this setting, according to an expert, marks an important milestone and will allow patients with unresectable or metastatic HER2-positive breast cancer to be treated in an earlier line, with the possibility of delaying disease progression.
Kisqali Combo Allows Patients With Advanced Breast Cancer to Live Longer, With ‘More Quality Time’
May 4th 2022Updated trial results showed that the use of Kisqali plus fulvestrant was associated with an approximate 33% decrease in risk of death for women with HR-positive, HER2-negative advanced breast cancer.
FDA Expedites Review of Nubeqa Combination for Metastatic, Hormone-Sensitive Prostate Cancer
May 3rd 2022Results from a phase 3 trial showed that the combination of Nubeqa, docetaxel and androgen-deprivation therapy significantly decreased the risk of death for men with a certain type of prostate cancer.
A HELPING HAND: Advice on Caring for Someone With Non-Small Cell Lung Cancer From Those Who Do It
May 1st 2022Care partners need help, too! That’s why this informational booklet was created. It’s full of practical advice from people who have been in your shoes, caring for someone with non-small cell lung cancer.